STOCK TITAN

Evolent Health (EVH) Financials

EVH NYSE
Trailing 12 months to September 30, 2026
Revenue $2.3B +14.1% YoY
Net Income -$507.7M n/m YoY
EPS (Diluted) -$4.54 n/m YoY
Operating Cash Flow $64.9M n/m YoY
Market Cap $388.0M as of Nov 19, 2026
Price / Sales 0.2x on $2.3B revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.0x on $372.9M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EVH SEC filings page.

Evolent Health, Inc (EVH) reported $2.3B in revenue over the twelve months to Sep 30, 2026, up 14.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EVH FY2025

Gross profit recovered while operating losses and leverage worsened, making financing structure more consequential than topline growth.

Operating income was -$410.1M despite gross profit of $399.9M, so overheads or other operating charges outweighed the reported gross profit. The $38.8M operating cash flow versus a $534.5M net loss indicates earnings were heavily affected by noncash items or working-capital movements.

Gross margin reached 21.3% in FY2025, up from 14.4% in FY2024. Paired with revenue down 26.6% and gross profit up 8.9%, this points to a changed direct-cost or revenue mix rather than straightforward scale expansion.

Debt-to-equity reached 2.3x from 0.5x in FY2024, showing a much thinner equity cushion. Total equity was $415.2M, while the current ratio improved to 1.3x from 0.8x; short-term coverage strengthened even as the longer-term financing structure deteriorated.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 22 / 100
Financial Health Score (5 of 6 dimensions) 22/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Evolent Health, Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
20

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Evolent Health, Inc scores 20/100 on it among other operating companies.

Growth
23

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Evolent Health, Inc scores 23/100 on it among other operating companies.

Leverage
15

Evolent Health, Inc carried $2.34 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 2.34. With no positive EBITDA in fiscal year 2025, Evolent Health, Inc is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 15/100 among other operating companies measured the same way.

Liquidity
35

Evolent Health, Inc held $1.31 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.31. Liquidity ranks operating companies on that ratio, and Evolent Health, Inc scores 35/100 among other operating companies.

Cash Flow
n/a

Not available for Evolent Health, Inc, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.

Returns
17

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Evolent Health, Inc scores 17/100 on it among other operating companies.

Altman Z-Score Distress
-0.46

Evolent Health, Inc scores -0.46, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.3B against total assets of $1.9B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
5/9

Evolent Health, Inc passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.

Earnings Quality Mixed
N/A

Evolent Health, Inc reported a net loss of $534.5M while generating $38.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Evolent Health, Inc reported an operating loss of $410.1M against $57.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$725.4M
YoY+51.3%
QoQ+11.2%
5Y CAGR+26.7%
10Y CAGR+28.3%

Evolent Health, Inc generated $725.4M in revenue in Q3 2026. This represents an increase of 51.3% from the same quarter a year earlier. Against the prior quarter it is up 11.2%.

EBITDA
$15.3M
YoY-37.5%
QoQ+27.5%

Evolent Health, Inc's EBITDA was $15.3M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 37.5% from the same quarter a year earlier. Against the prior quarter it is up 27.5%.

Net Income
-$23.6M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

Evolent Health, Inc reported a net loss of $23.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.21
YoYn/m
QoQn/m
5Y CAGRn/m

Evolent Health, Inc earned -$0.21 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$148.3M
YoY+27.1%
QoQ+28.1%
5Y CAGR-10.1%
10Y CAGR+3.1%

Evolent Health, Inc held $148.3M in cash against $969.5M in long-term debt as of Q3 2026.

Shares Outstanding
113M
YoY+1.3%
QoQ0.0%
5Y CAGR+4.8%

Evolent Health, Inc had 113M shares outstanding in Q3 2026. This represents an increase of 1.3% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
12.2%
YoY-8.6pp
QoQ-0.2pp

Evolent Health, Inc's gross margin was 12.2% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 8.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.2 percentage points.

Operating Margin
-0.9%
YoY-1.0pp
QoQ+0.6pp

Evolent Health, Inc's operating margin was -0.9% in Q3 2026, reflecting core business profitability. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.6 percentage points.

Net Margin
-3.3%
YoY+1.1pp
QoQ+1.1pp
5Y change+2.6pp
10Y change+15.4pp

Evolent Health, Inc's net profit margin was -3.3% in Q3 2026, showing the share of revenue converted to profit. This is up 1.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Return on Equity
-6.3%
YoY-3.8pp
QoQ+1.1pp
5Y change-4.2pp
10Y change-4.3pp

Evolent Health, Inc's quarterly ROE was -6.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 3.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Capital Allocation

None of these metrics is reported for Q3 2026.

EVH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVH quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$725.4M+51.3%$652.5M+46.9%$496.2M+2.6%$468.7M-27.5%$479.5M-22.8%$444.3M-31.3%$483.6M-24.4%$646.5M+16.3%
Cost of Revenue$636.9M+67.7%$571.7M+66.2%$412.5M+8.2%N/A$379.8M-29.8%$343.9M-36.3%$381.2M-28.8%N/A
Gross Profit$88.4M-11.4%$80.8M-19.5%$83.8M-18.2%N/A$99.8M+23.6%$100.4M-6.0%$102.5M-1.6%N/A
SG&A Expenses$73.1M-5.8%$68.8M-8.5%$72.8M-7.1%N/A$77.6M+15.7%$75.2M+8.7%$78.4M-0.9%N/A
Operating Income-$6.2M-798.4%-$9.6Mn/m-$10.6Mn/mN/A$886Kn/m-$1.2M-115.0%-$1.6Mn/mN/A
EBITDA$15.3M-37.5%$12.0M-45.4%$11.0M-51.2%N/A$24.5M+82.4%$22.0M-41.7%$22.4M+39.4%N/A
Interest Expense$17.0M+3.2%$16.9M+45.3%$16.9M+62.4%N/A$16.5M+174.1%$11.6M+93.5%$10.4M+73.2%N/A
Income Tax$1.1M+23.4%$2.7Mn/m$910K-38.1%N/A$906Kn/m-$825Kn/m$1.5M+160.2%N/A
Net Income-$23.6Mn/m-$28.4Mn/m-$26.6Mn/m-$429.1Mn/m-$20.9Mn/m-$19.9M-1346.7%-$64.6Mn/m-$22.8Mn/m
EPS (Basic)-$0.21n/m-$0.25n/m-$0.24n/m-$3.84n/m-$0.24n/m-$0.44n/m-$0.63n/m-$0.27n/m
EPS (Diluted)-$0.21n/m-$0.25n/m-$0.24n/m-$3.84n/m-$0.24n/m-$0.44n/m-$0.63n/m-$0.27n/m
Diluted Shares (Avg)113M-0.9%113M-2.9%112M-3.0%N/A114M-0.7%116M+1.0%115M+1.0%N/A

Not reported in any period shown, so not listed: R&D Expenses.

EVH Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVH quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$2.0B-20.0%$2.0B-19.9%$1.9B-29.2%$1.9B-25.4%$2.5B-1.9%$2.5B-0.5%$2.7B+0.4%$2.5B-5.1%
Current Assets$617.1M+8.2%$610.5M+8.6%$502.0M-31.0%$506.4M-16.6%$570.1M+4.8%$562.3M+7.9%$727.9M+8.8%$607.1M-11.2%
Cash & Equivalents$148.3M+27.1%$115.7M-23.4%$142.0M-42.4%$151.9M+45.7%$116.7M+20.8%$151.0M+49.1%$246.5M+49.3%$104.2M-46.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts Receivable$442.8M+14.5%$449.1M+25.2%$314.2M-27.0%$309.9M-25.3%$386.6M-5.2%$358.8M-4.0%$430.5M+0.6%$414.7M-7.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$694.4M-35.4%$694.4M-38.9%$694.4M-38.9%$694.5M-38.9%$1.1B-5.4%$1.1B+1.9%$1.1B+1.9%$1.1B+1.9%
Total Liabilities$1.6B-1.4%$1.6B+18.8%$1.5B-2.8%$1.5B+9.7%$1.6B+26.3%$1.3B+8.1%$1.5B+7.8%$1.4B-5.7%
Current Liabilities$489.9M+14.0%$492.8M-11.6%$381.2M-48.4%$385.3M-46.2%$429.9M-17.9%$557.5M+15.3%$739.1M+12.2%$715.5M+6.1%
Non-Current Liabilities$1.1B-6.9%$1.1B+40.6%$1.1B+40.2%$1.1B+72.4%$1.2B+57.0%$779.2M+3.4%$785.6M+4.0%$637.5M-16.1%
Long-Term Debt$969.5M-8.1%$966.5M+49.0%$973.5M+50.3%$970.5M+97.9%$1.1B+75.9%$648.5M+8.3%$647.5M+8.3%$490.5M-17.8%
Total Equity$372.9M-55.7%$383.2M-57.2%$396.4M-57.6%$415.2M-58.5%$842.2M-18.9%$896.0M-15.0%$935.5M-10.7%$1.0B-6.2%
Retained Earnings-$1.4Bn/m-$1.4Bn/m-$1.3Bn/m-$1.3Bn/m-$886.2Mn/m-$865.3Mn/m-$845.4Mn/m-$780.8Mn/m

Not reported in any period shown, so not listed: Inventory.

EVH Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVH quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$26.4M+66.8%-$9.3Mn/m-$984K-121.6%$48.8Mn/m$15.8M-15.3%-$30.3M-241.6%$4.6M-7.0%-$26.2M-129.3%
Depreciation & Amortization$21.5M-9.0%$21.6M-6.8%$21.6M-10.4%$45.0M+53.7%$23.6M-20.5%$23.1M-22.5%$24.1M-18.5%$29.3M-1.0%
Stock-Based Compensation$14.8M+0.8%$15.2M+31.3%$10.6M-3.9%N/A$14.7M+1.8%$11.6M-8.5%$11.1M-41.0%N/A
Investing Cash Flow-$7.1Mn/m-$6.7Mn/m-$6.4Mn/m$82.2Mn/m-$8.8Mn/m-$60.5Mn/m-$13.1Mn/m-$19.9Mn/m
Financing Cash Flow-$4.6Mn/m-$11.0Mn/m-$4.0M-103.7%-$93.0M-196.0%-$41.8Mn/m-$8.9Mn/m$107.9M+624.7%$96.9Mn/m
Share BuybacksN/AN/AN/A$0n/mN/AN/AN/A$0

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid.

EVH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

EVH quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin12.2%-8.6pp12.4%-10.2pp16.9%-4.3ppN/A20.8%+7.8pp22.6%+6.1pp21.2%+4.9ppN/A
Operating Margin-0.9%-1.0pp-1.5%-1.2pp-2.1%-1.8ppN/A0.2%+2.8pp-0.3%-1.5pp-0.3%+1.8ppN/A
Net Margin-3.3%+1.1pp-4.3%+0.1pp-5.4%+8.0pp-91.5%-88.0pp-4.3%-0.6pp-4.5%-4.7pp-13.4%-10.7pp-3.5%+2.5pp
Return on Equity-6.3%-3.8pp-7.4%-5.2pp-6.7%+0.2pp-103.4%-101.1pp-2.5%-0.2pp-2.2%-2.4pp-6.9%-5.3pp-2.3%+0.9pp
Return on Assets-1.2%-0.3pp-1.4%-0.6pp-1.4%+1.0pp-22.6%-21.7pp-0.9%+0.1pp-0.8%-0.9pp-2.4%-1.8pp-0.9%+0.4pp
Current Ratio1.26-0.1x1.24+0.2x1.32+0.3x1.31+0.5x1.33+0.3x1.01-0.1x0.980.0x0.85-0.2x
Debt-to-Equity2.60+1.3x2.52+1.8x2.46+1.8x2.34+1.8x1.25+0.7x0.72+0.2x0.69+0.1x0.49-0.1x
Liabilities-to-Equity4.26+2.3x4.15+2.7x3.74+2.1x3.57+2.2x1.91+0.7x1.49+0.3x1.63+0.3x1.350.0x
Asset Turnover0.37+0.2x0.33+0.2x0.26+0.1x0.250.0x0.20-0.1x0.18-0.1x0.18-0.1x0.250.0x

Not reported in any period shown, so not listed: FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Evolent Health, Inc EVH FY2025 $1.9B -$534.5M -28.5% $388.0M 22/100
NRC Health NRC FY2025 $137.4M $11.3M 8.2% $530.3M 51/100
Claritev Corporation CTEV FY2025 $965.4M -$284.3M -29.4% $324.9M 18/100
Carlsmed, Inc. CARL FY2025 $50.5M -$29.6M -58.7% $471.9M 54/100
SOPHiA GENETICS SA SOPH FY2025 $77.3M -$79.0M N/A $639.9M 63/100
Phreesia, Inc. PHR FY2026 $480.6M $2.3M 0.5% $736.8M 47/100

Frequently Asked Questions

Evolent Health, Inc (EVH) reported $1.9B in total revenue for fiscal year 2025. This represents a -26.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Evolent Health, Inc (EVH) revenue declined by 26.6% year-over-year, from $2.6B to $1.9B in fiscal year 2025.

No, Evolent Health, Inc (EVH) reported a net loss of $507.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $534.5M, with a net profit margin of -28.5%.

Evolent Health, Inc (EVH) reported diluted earnings per share of -$5.07 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Evolent Health, Inc (EVH) had EBITDA of -$294.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Evolent Health, Inc (EVH) had $151.9M in cash and equivalents against $970.5M in long-term debt.

Evolent Health, Inc (EVH) had a gross margin of 21.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Evolent Health, Inc (EVH) had an operating margin of -21.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Evolent Health, Inc (EVH) had a net profit margin of -28.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Evolent Health, Inc (EVH) has a return on equity of -128.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Evolent Health, Inc (EVH) generated $38.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Evolent Health, Inc (EVH) had $1.9B in total assets as of fiscal year 2025, including both current and long-term assets.

Yes, Evolent Health, Inc (EVH) spent $40.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

Evolent Health, Inc (EVH) had 112M shares outstanding as of fiscal year 2025.

Evolent Health, Inc (EVH) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.

Evolent Health, Inc (EVH) had a debt-to-equity ratio of 2.34 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Evolent Health, Inc (EVH) had a liabilities-to-equity ratio of 3.57 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Evolent Health, Inc (EVH) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Evolent Health, Inc (EVH) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $388.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Evolent Health, Inc (EVH) trades at 0.2x sales, its market capitalization divided by $2.3B revenue, trailing 12 months to September 30, 2026. The market capitalization is $388.0M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Evolent Health, Inc (EVH) has an Altman Z-Score of -0.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Evolent Health, Inc (EVH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Evolent Health, Inc (EVH) reported a net loss of $534.5M while generating $38.8M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Evolent Health, Inc (EVH) reported an operating loss of $410.1M against $57.5M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Evolent Health, Inc (EVH) scores 22 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Evolent Health, Inc it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top